| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA512: Tivozanib for treating advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | tivozanib (Fotivda®) |
| Formulation | 890 µg and 1340 µg hard capsule |
| Reference number | 1640 |
| Indication | First-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC |
| Company | EUSA Pharma (Europe) Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2017 |
| NICE guidance | |